Study guide
16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism
NBCRNA CRNA Certified Registered Nurse Anesthetist NCE
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Cardiovascular, Respiratory & CNS Physiology & Pathophysiology
1.1 Cardiovascular Physiology, Hemodynamics & Ischemic Heart Disease 1.2 Respiratory Physiology, Lung Volumes & Chronic Pulmonary Pathophysiology 1.3 Central & Autonomic Nervous System Physiology & Neurological Disorders
2 Chapter 2: Hepatorenal, Endocrine & Hematologic/Immune Systems
2.1 Renal Physiology, Glomerular Filtration & Acid-Base Balance 2.2 Hepatic Physiology, Drug Clearance & Gastrointestinal Considerations 2.3 Endocrine Disorders, Hematology, Coagulation & Immune Mechanisms
3 Chapter 3: Anesthetic Pharmacology: Inhalation Agents, Intravenous Anesthetics & Sedatives
3.1 Inhalation Anesthetics: Uptake, Distribution, Blood/Gas Solubility & MAC 3.2 Intravenous Hypnotics: Propofol, Etomidate, Ketamine & Barbiturates 3.3 Opioid Agonists/Antagonists, Benzodiazepines & Reversal Pharmacology
4 Chapter 4: Anesthetic Pharmacology: Neuromuscular Blockers, Local Anesthetics & Physics
4.1 Neuromuscular Blocking Agents & Reversal: Anticholinesterases vs Sugammadex 4.2 Local Anesthetics: Mechanism, Potency, Toxicity (LAST) & Vasoconstrictors 4.3 Applied Physics, Gas Laws, Fluid Dynamics & Anesthesia Mathematics
5 Chapter 5: Anesthesia Delivery Systems & Gas Supplies
5.1 Medical Gas Supply Systems, Cylinders, Regulators & Safety Index Systems (PISS/DISS) 5.2 Anesthesia Machine High, Intermediate & Low Pressure Systems & Failsafe Mechanisms 5.3 Vaporizer Technology: Variable-Bypass vs Desflurane Vaporizers & Machine Checkout
6 Chapter 6: Breathing Circuits, CO2 Absorption & Ventilators
6.1 Breathing Circuits: Circle System, Mapleson Classifications & Dead Space 6.2 Carbon Dioxide Absorption: Soda Lime Chemistry, Desiccation, Carbon Monoxide & Compound A 6.3 Anesthesia Ventilators, Pressure/Volume Modes, APL Valves & Waste Gas Scavenging
7 Chapter 7: Airway Equipment & Advanced Airway Instrumentation
7.1 Face Masks, Supraglottic Airways (LMA Types) & Endotracheal Tubes 7.2 Direct Laryngoscopy (Mac/Miller) & Video Laryngoscopy 7.3 Fiberoptic Intubation, Bronchial Blockers, Double-Lumen Tubes & Surgical Airways
8 Chapter 8: Patient Monitoring, Hemodynamics & Electrosurgical Safety
8.1 Noninvasive Monitoring: Pulse Oximetry, Capnography Waveforms & Temperature 8.2 Invasive Hemodynamics: Arterial Lines, CVP & Pulmonary Artery Catheters 8.3 Neuromuscular Monitoring (TOF/PTC), Depth of Anesthesia (EEG/BIS) & Electrical Safety
9 Chapter 9: Preoperative Assessment, Risk Stratification & Preparation
9.1 Preoperative History, Physical Examination & ASA Physical Status Classification 9.2 Cardiac & Pulmonary Risk Stratification, Diagnostic Testing & Optimization 9.3 Preoperative Fasting Guidelines, Aspiration Prophylaxis & Premedication
10 Chapter 10: Fluid Management, Blood Component Therapy & Coagulation Monitoring
10.1 Crystalloids vs Colloids, Maintenance & Deficit Calculations 10.2 Blood Component Therapy, Transfusion Triggers & Massive Transfusion Protocols 10.3 Point-of-Care Coagulation: TEG, ROTEM & Perioperative Coagulopathies
11 Chapter 11: Airway Management Strategies & Difficult Airway Algorithms
11.1 Difficult Airway Assessment: Mallampati, Cormack-Lehane & Airway Predictors 11.2 ASA Difficult Airway Algorithm: Anticipated vs Unanticipated Difficult Airway 11.3 "Cannot Intubate, Cannot Oxygenate" (CICO) & Emergency Front-of-Neck Access (eFONA)
12 Chapter 12: General Anesthesia: Induction, Maintenance, Emergence & TIVA
12.1 Rapid Sequence Induction (RSI), Cricoid Pressure & Intubation Protocols 12.2 Balanced Anesthesia vs Total Intravenous Anesthesia (TIVA) Principles 12.3 Emergence, Extubation Criteria, Deep vs Awake Extubation & Laryngospasm
13 Chapter 13: Regional Anesthesia: Neuraxial Blocks
13.1 Spinal Anesthesia: Anatomy, Physiology, High Spinal & Complications 13.2 Epidural & Combined Spinal-Epidural (CSE) Techniques & PDPH 13.3 Neuraxial Anticoagulation Guidelines (ASRA) & Epidural Hematoma
14 Chapter 14: Regional Anesthesia: Peripheral Nerve Blocks & Ultrasound Guidance
14.1 Upper Extremity Peripheral Nerve Blocks: Interscalene, Supraclavicular, Axillary 14.2 Lower Extremity & Truncal Blocks: Femoral, Sciatic, TAP & ESP Blocks 14.3 Ultrasound Physics, Needle Visualization & LAST Rescue Protocols
15 Chapter 15: Perioperative Safety, Positioning, PACU, Ethics & Professional Practice
15.1 Surgical Positioning Complications: Nerve Injuries & Physiologic Changes 15.2 PACU Discharge Criteria, PONV Management, Hypoxemia & Emergence Delirium 15.3 Malignant Hyperthermia Protocol & Operating Room Crisis Management 15.4 CRNA Ethics, Informed Consent, Scope of Practice & Wellness Initiatives
16 Chapter 16: Obstetric & Gynecologic Anesthesia
16.1 Maternal Physiology & Pharmacokinetics Across Trimesters 16.2 Labor Analgesia & Anesthesia for Cesarean Delivery 16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism 16.4 Nonobstetric Surgery in the Pregnant Patient
17 Chapter 17: Pediatric Anesthesia
17.1 Pediatric Anatomy, Physiology, Airway & Developmental Pharmacology 17.2 Pediatric Induction, Maintenance, Fluids & Emergence Agitation 17.3 Pediatric Respiratory Emergencies: Croup, Epiglottitis & Laryngospasm
18 Chapter 18: Geriatric, Bariatric & Ambulatory Anesthesia
18.1 Geriatric Physiology, Pharmacodynamics & Postoperative Delirium/POCD 18.2 Bariatric Anesthesia: Obesity Hypoventilation, OSA & Dosing Adjustments 18.3 Ambulatory Surgery Selection Criteria & ERAS Protocols
19 Chapter 19: Cardiac, Vascular & Thoracic Anesthesia
19.1 Valvular Heart Disease, CAD & Cardiopulmonary Bypass Management 19.2 Vascular Anesthesia: Carotid Endarterectomy & Aortic Cross-Clamping 19.3 Thoracic Anesthesia: One-Lung Ventilation & Hypoxic Pulmonary Vasoconstriction
20 Chapter 20: Neurosurgical, Intra-Abdominal, Extrathoracic, Head/Neck & Trauma Anesthesia
20.1 Neurosurgical Anesthesia: ICP Dynamics, Craniotomy & Venous Air Embolism 20.2 Intra-Abdominal, Laparoscopy & Endocrine Tumor Anesthesia (Pheochromocytoma, Carcinoid) 20.3 ENT/Shared Airway, Extrathoracic Procedures & Trauma/Burn Resuscitation
21 Chapter 21: Neurologic, Gastrointestinal & Substance-Related Pathophysiology and Pharmacology
21.1 Neurodegenerative & Demyelinating Disease and Antiparkinsonian Pharmacology 21.2 Gastrointestinal & Exocrine Pancreatic Disorders: Esophageal, Gastric, Pancreatitis & Malabsorption 21.3 Cannabinoids, Herbal Remedies & Dietary Supplements
22 Chapter 22: Imaging Safety, Patient Warming & Infusion Technology
22.1 Fluoroscopy, Radiography & Radiation Safety in Anesthetizing Locations 22.2 Patient Warming Equipment & Rapid Infusion Devices
23 Chapter 23: Pain Medicine: Theory, Chronic Pain & Interventional Procedures
23.1 Pain Theory: Nociception, Sensitization & Chronic Pain Pathophysiology 23.2 Chronic Pain Management, Medication-Assisted Therapy & the Opioid-Tolerant Patient 23.3 Interventional Pain Procedures & Anesthesia for Pain Management Cases
24 Chapter 24: Professional Practice: Research Ethics, Error Disclosure & Provider Infection Control
24.1 Research Ethics, IRB Oversight & Protection of Human Subjects 24.2 Disclosure of Errors and Injuries, Adverse Event Reporting & Just Culture 24.3 Provider Infection Control: PPE, Air Handling & Occupational Exposure
25 Chapter 25: Neurosurgical Subspecialty Procedures
25.1 Cerebral Aneurysm Clipping, AVM Resection & Subarachnoid Hemorrhage 25.2 Transsphenoidal Hypophysectomy & Pituitary Surgery 25.3 Stereotactic Procedures, Deep Brain Stimulation & Awake Craniotomy 25.4 CSF Diversion, Burr Holes, Ventriculoperitoneal Shunts & Decompressive Craniectomy
26 Chapter 26: Head, Neck, Nasal, Dental & Ophthalmic Anesthesia
26.1 Nasal & Sinus Surgery, Nasotracheal Intubation & Craniofacial Procedures 26.2 Dental, Orthodontic, Oral-Maxillofacial & Ophthalmic Anesthesia 26.3 Neck Tumors, Radical Neck Dissection, Lymph Node Biopsy & Thyroid/Parathyroid Surgery
27 Chapter 27: Orthopedic & Extremity Anesthesia
27.1 Total Joint Arthroplasty, Bone Cement Implantation Syndrome & Tourniquet Physiology 27.2 Closed Reduction, Hand and Foot Procedures & Intravenous Regional (Bier) Block
28 Chapter 28: Non-Operating-Room Anesthesia: Interventional, Imaging & Radiation Therapy
28.1 Interventional and Neurointerventional Radiology Anesthesia 28.2 Radiation Therapy, Diagnostic Imaging & MRI-Suite Anesthesia
29 Chapter 29: Special Populations: Substance Use Disorder, Immunocompromised & Oncology Patients
29.1 Acute Intoxication, Withdrawal Syndromes & Perioperative Complications 29.2 Anesthesia for the Immunocompromised & Oncology Patient
16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism
Key Takeaways Explain This Topic AI
Preeclampsia is an endothelial disorder defined by new-onset hypertension (BP ≥140/90 after 20 weeks) with proteinuria or severe features (BP ≥160/110, platelets <100,000/mm³, transaminases 2x normal, serum Cr >1.1 mg/dL, pulmonary edema, or cerebral/visual symptoms).
Magnesium sulfate (4-6 g loading dose over 15-20 min, then 1-2 g/h infusion) is the gold standard for eclampsia seizure prophylaxis (therapeutic level 4-7 mEq/L); loss of deep tendon reflexes occurs at 8-10 mEq/L, respiratory arrest at 10-12 mEq/L, and cardiac arrest at >12-15 mEq/L, treated immediately with Calcium Gluconate (1 g IV).
Magnesium potentiates both depolarizing and non-depolarizing neuromuscular blocking agents by inhibiting presynaptic acetylcholine release and decreasing endplate sensitivity; neuromuscular monitor guidance and dose reductions are mandatory.
Obstetric hemorrhage requires rapid differential diagnosis: Placenta Previa causes painless bright red bleeding, whereas Placental Abruption causes painful dark bleeding, a hypertonic/rigid uterus, and severe consumptive DIC driven by massive tissue factor release.
Amniotic Fluid Embolism (AFE) triggers sudden cardiovascular collapse, profound hypoxemia, and consumptive DIC; emergency management includes high-quality CPR (with perimortem hysterotomy within 4-5 minutes if cardiac arrest occurs) and the 'A-OK' protocol: Atropine (0.8-1 mg), Ondansetron (8 mg), and Ketorolac (30 mg).
Last updated: August 2026
16.3 Obstetric Emergencies: Preeclampsia, Hemorrhage & Amniotic Fluid Embolism
Obstetric emergencies develop with breathtaking speed and carry substantial risks of maternal and neonatal morbidity and mortality. The nurse anesthetist must maintain mastery over hypertensive disorders of pregnancy, the pharmacology of magnesium sulfate, the differential diagnosis of catastrophic peripartum hemorrhage, and the resuscitation of amniotic fluid embolism.
1. Preeclampsia, Severe Features & HELLP Syndrome
Preeclampsia affects 5 − 8 % 5 - 8\% 5 − 8% of all pregnancies. Its root etiology is abnormal trophoblastic invasion of the maternal spiral arteries , leaving them as narrow, high-resistance, muscular vessels. The resulting placental ischemia triggers the systemic release of anti-angiogenic factors (such as soluble fms-like tyrosine kinase-1 [sFlt-1] and soluble endoglin [sEng]), provoking widespread maternal vascular endothelial dysfunction , intense vasospasm, microvascular thrombosis, increased capillary permeability, and end-organ hypoperfusion. +---------------------------------------------------------------------------------------------------------+
- | PREECLAMPSIA SEVERE FEATURES CRITERIA |
- +----------------------------+----------------------------------------------------------------------------+
- | Organ System / Domain | Diagnostic Criteria for Severe Features (Any 1 elevates to Severe) |
- +----------------------------+----------------------------------------------------------------------------+
- | **Blood Pressure** | • Systolic BP $\ge 160 \text{ mmHg}$ OR Diastolic BP $\ge 110 \text{ mmHg}$ |
- | | on 2 occasions at least 4 hours apart (or verified in minutes for tx) |
- +----------------------------+----------------------------------------------------------------------------+
- | **Thrombocytopenia** | • Platelet count $< 100,000 /\text{mm}^3$ |
- +----------------------------+----------------------------------------------------------------------------+
- | **Renal Insufficiency** | • Serum Creatinine $> 1.1 \text{ mg/dL}$ (or doubling of baseline |
- | | in the absence of underlying renal disease) |
- +----------------------------+----------------------------------------------------------------------------+
- | **Hepatic Impairment** | • Serum transaminases (AST, ALT) $> 2\times$ upper limit of normal |
- | | • Severe, persistent epigastric or right upper quadrant pain |
- +----------------------------+----------------------------------------------------------------------------+
- | **Pulmonary System** | • **Pulmonary Edema** (dyspnea, orthopnea, hypoxemia, rales) |
- +----------------------------+----------------------------------------------------------------------------+
- | **Cerebral / Visual** | • New-onset headache unresponsive to medication, photopsia, scotomata, |
- | | cortical blindness, hyperreflexia with clonus |
- +----------------------------+----------------------------------------------------------------------------+
- HELLP Syndrome
HELLP syndrome develops in 10 − 20 % 10 - 20\% 10 − 20% of women with severe preeclampsia and represents an acute microangiopathic hemolytic process:
H (Hemolysis): Microangiopathic hemolytic anemia with fragmented RBCs ( schistocytes ) on peripheral blood smear, elevated total bilirubin ( ≥ 1.2 mg/dL \ge 1.2 \text{ mg/dL} ≥ 1.2 mg/dL ), low haptoglobin, and markedly elevated LDH ( > 600 IU/L > 600 \text{ IU/L} > 600 IU/L ) .
EL (Elevated Liver Enzymes): AST and ALT ≥ 2 × \ge 2\times ≥ 2 × upper limit of normal.
LP (Low Platelets): Platelet count < 100 , 000 / mm 3 < 100,000 /\text{mm}^3 < 100 , 000/ mm 3 . Patients are at risk for subcapsular hepatic hematoma and catastrophic hepatic rupture.
Acute Antihypertensive Pharmacotherapy
The goal of antihypertensive therapy in preeclampsia is to reduce maternal blood pressure to a safe range ( 140 − 150 / 90 − 100 mmHg 140 - 150 / 90 - 100 \text{ mmHg} 140 − 150/90 − 100 mmHg ) to prevent hemorrhagic stroke and placental abruption while avoiding excessive hypotension that would compromise uteroplacental perfusion.
Labetalol: Combined α 1 \alpha_1 α 1 and non-selective β \beta β -blocker ( 1 : 7 1:7 1 : 7 ratio IV). Initial dose: 20 mg 20 \text{ mg} 20 mg IV , followed by 40 − 80 mg 40 - 80 \text{ mg} 40 − 80 mg every 10 − 20 minutes 10 - 20 \text{ minutes} 10 − 20 minutes (maximum cumulative dose: 300 mg 300 \text{ mg} 300 mg ), or continuous infusion at 1 − 2 mg/min 1 - 2 \text{ mg/min} 1 − 2 mg/min . Avoid in asthma, severe bradycardia, or uncompensated heart failure.
Hydralazine: Direct arteriolar vasodilator. Initial dose: 5 − 10 mg 5 - 10 \text{ mg} 5 − 10 mg IV every 20 minutes 20 \text{ minutes} 20 minutes (maximum dose: 20 − 30 mg 20 - 30 \text{ mg} 20 − 30 mg ). Can cause reflex tachycardia and headache.
Nicardipine: Dihydropyridine calcium channel blocker. Initial infusion: 5 mg/hr 5 \text{ mg/hr} 5 mg/hr IV , titrated by 2.5 mg/hr 2.5 \text{ mg/hr} 2.5 mg/hr every 5 − 15 minutes 5 - 15 \text{ minutes} 5 − 15 minutes (maximum: 15 mg/hr 15 \text{ mg/hr} 15 mg/hr ). Highly titratable and effective.
2. Magnesium Sulfate: Pharmacology, Toxicity & Drug Interactions
Magnesium sulfate ( M g S O 4 MgSO_4 M g S O 4 ) is the anticonvulsant of choice for the prevention and treatment of eclamptic seizures (superior to phenytoin, diazepam, and nimodipine). Magnesium acts by:
Competing with calcium at presynaptic voltage-gated calcium channels, decreasing acetylcholine (ACh) release at the neuromuscular junction.
Acting as a central NMDA receptor antagonist , suppressing neuronal hyperexcitability.
Inducing cerebral and peripheral vasodilation, relieving cerebral vasospasm and reducing blood-brain barrier permeability. +---------------------------------------------------------------------------------------------------------+
- | MAGNESIUM SULFATE CLINICAL & TOXICITY SPECTRUM |
- +-------------------------+-------------------------+-----------------------------------------------------+
- | Serum Mg²⁺ Level (mEq/L)| Serum Mg²⁺ (mg/dL) | Clinical Manifestations & Physiological Effects |
- +-------------------------+-------------------------+-----------------------------------------------------+
- | **1.5 – 2.5 mEq/L** | 1.8 – 3.0 mg/dL | • Normal baseline physiological level |
- +-------------------------+-------------------------+-----------------------------------------------------+
- | **4.0 – 7.0 mEq/L** | **4.8 – 8.4 mg/dL** | • **Therapeutic Range for Eclampsia Seizure Proph.**|
- | | (2.0 – 3.5 mmol/L) | • Mild ECG changes (PQ prolongation), mild sedation |
- +-------------------------+-------------------------+-----------------------------------------------------+
- | **8.0 – 10.0 mEq/L** | 9.6 – 12.0 mg/dL | • **LOSS OF DEEP TENDON REFLEXES (PATELLAR / DTRs)**|
- | | | • First objective clinical sign of impending tox! |
- +-------------------------+-------------------------+-----------------------------------------------------+
- | **10.0 – 12.0 mEq/L** | 12.0 – 14.4 mg/dL | • **RESPIRATORY DEPRESSION & APNEA** |
- | | | • SA and AV nodal heart block, QRS widening |
- +-------------------------+-------------------------+-----------------------------------------------------+
- | **> 12.0 – 15.0 mEq/L** | > 14.4 – 18.0 mg/dL | • **CARDIAC ARREST (ASYSTOLE / VFIB)** |
- | | | • Complete flaccid quadriplegia |
+-------------------------+-------------------------+-----------------------------------------------------+ [MAGNESIUM TOXICITY HIERARCHY & PROGRESSION]
- Serum Mg2+ (mEq/L)
- >12 mEq/L | -----------------------------------------> **CARDIAC ARREST (Asystole)**
- |
- 10-12 | -----------------------------------------> **RESPIRATORY ARREST & AV Block**
- |
- 8-10 | -----------------------------------------> **LOSS OF PATELLAR DTRs** (Check 1st!)
- |
- 4-7 | =========================================> **THERAPEUTIC WINDOW** (Seizure Proph)
- |
- 1.5-2.5 | -----------------------------------------> Normal Baseline
- Magnesium Administration & Antidote Protocol
Dosing Regimen: Loading dose of 4 − 6 g 4 - 6 \text{ g} 4 − 6 g IV over 15 − 20 minutes 15 - 20 \text{ minutes} 15 − 20 minutes , followed by a continuous maintenance infusion of 1 − 2 g/hr 1 - 2 \text{ g/hr} 1 − 2 g/hr for 24 hours 24 \text{ hours} 24 hours postpartum. Magnesium is cleared 100 % 100\% 100% renally ; in parturients with renal impairment ( C r > 1.1 mg/dL Cr > 1.1 \text{ mg/dL} C r > 1.1 mg/dL or oliguria < 30 mL/hr <30 \text{ mL/hr} < 30 mL/hr ), the maintenance infusion must be reduced or withheld while frequently checking serum levels.
Antidote for Toxicity:
Immediately stop the M g S O 4 MgSO_4 M g S O 4 infusion.
Administer Calcium Gluconate 1 g 1 \text{ g} 1 g IV ( 10 mL 10 \text{ mL} 10 mL of 10 % 10\% 10% solution) slowly over 3 − 5 minutes 3 - 5 \text{ minutes} 3 − 5 minutes (or Calcium Chloride 300 − 500 mg 300 - 500 \text{ mg} 300 − 500 mg IV via central access). Calcium directly antagonizes magnesium at both the neuromuscular junction and cardiac conducting membranes.
Support airway and ventilation with 100 % O 2 100\% \text{ O}_2 100% O 2 ; perform endotracheal intubation if the patient is apneic.
Anesthetic Interaction with Neuromuscular Blockers
Magnesium markedly potentiates both depolarizing and non-depolarizing neuromuscular blocking agents (NMBAs) :
Non-depolarizing NMBAs (Rocuronium, Vecuronium, Cisatracurium): Magnesium reduces presynaptic ACh release and stabilizes the postjunctional motor endplate. The potency and clinical duration of action of non-depolarizers can be increased by 200% to 400% . Doses must be reduced by 50 − 75 % 50 - 75\% 50 − 75% , and quantitative train-of-four (TOF) monitoring is mandatory.
Depolarizing NMBAs (Succinylcholine): Succinylcholine duration may be prolonged due to competitive membrane stabilization. However, standard intubating doses ( 1.0 − 1.5 mg/kg 1.0 - 1.5 \text{ mg/kg} 1.0 − 1.5 mg/kg ) should NOT be reduced for RSI to ensure rapid, reliable intubating conditions.
Neuraxial Platelet Safety Thresholds in Preeclampsia
Neuraxial anesthesia (early labor epidural / spinal for C-section) is the preferred anesthetic modality in preeclampsia because it avoids the dangerous hypertensive surges and airway hazards associated with general endotracheal intubation.
Platelet Count ≥ 70 , 000 − 80 , 000 / mm 3 \ge 70,000 - 80,000 /\text{mm}^3 ≥ 70 , 000 − 80 , 000/ mm 3 : Neuraxial placement (and catheter removal) is considered safe according to SOAP/ASRA consensus guidelines, provided the platelet count is stable (not precipitously falling), coagulation studies (PT/INR, aPTT, fibrinogen) are normal, and there is no concurrent anticoagulant therapy.
Platelet Count 50 , 000 − 70 , 000 / mm 3 50,000 - 70,000 /\text{mm}^3 50 , 000 − 70 , 000/ mm 3 : Individualized risk-benefit decision based on trend of platelet decline, presence of platelet dysfunction, viscoelastic testing (TEG/ROTEM Maximum Clot Firmness), and airway difficulty assessment.
Platelet Count < 50 , 000 / mm 3 < 50,000 /\text{mm}^3 < 50 , 000/ mm 3 : Neuraxial anesthesia is contraindicated due to unacceptable risk of spinal-epidural hematoma.
3. Third-Trimester Obstetric Hemorrhage
Obstetric hemorrhage remains a leading cause of maternal mortality worldwide. Rapid clinical discrimination among the major causes is essential. +---------------------------------------------------------------------------------------------------------+
- | THIRD-TRIMESTER HEMORRHAGE DIFFERENTIAL MATRIX |
- +------------------+------------------------------+---------------------------+---------------------------+
- | Condition | Clinical Presentation | Pathophysiology | Anesthetic & Obstetric |
- | | & Bleeding Characteristics | & Mechanism | Management |
- +------------------+------------------------------+---------------------------+---------------------------+
- | **Placenta | • **Painless, bright red** | • Placenta implants over | • **NO DIGITAL VAGINAL** |
- | Previa** | vaginal bleeding | or near internal os | **EXAM!** (avoids tear) |
- | | • Soft, non-tender uterus | • Tearing of placental | • Elective Cesarean delivery|
- | | • Normal fetal heart rate | attachments as lower | • Fluid resuscitation; |
- | | until maternal shock | uterine segment thins | type & crossmatch |
- +------------------+------------------------------+---------------------------+---------------------------+
- | **Placental | • **Painful, dark red** | • Premature detachment of | • **Massive release of |
- | Abruption** | vaginal bleeding (or 20% | normally implanted | decidual Tissue Factor |
- | *(Abruptio)* | concealed behind placenta) | placenta from myometrium| causes **Consumptive** |
- | | • **Hypertonic/woody,** | • Retroplacental hematoma | **DIC** & hypofibrinogen|
- | | **severely tender uterus** | expands under pressure | • Emergent C-section; MTP;|
- | | • Severe fetal distress | • Maternal HTN is #1 risk | platelets & cryo target |
- +------------------+------------------------------+---------------------------+---------------------------+
- | **Placenta | • Massive, torrential | • Defective decidua | • Multidisciplinary team; |
- | Accreta | bleeding upon attempted | basalis allows chorionic| arterial line, 2 large- |
- | Spectrum (PAS)**| manual placental removal | villi to invade uterine | bore IVs, Level 1 infuser|
- | | • Visible invasive vascularity| wall (Accreta: surface; | • Massive Transfusion (MTP)|
- | | on ultrasound / MRI | Increta: deep muscle; | • Planned Cesarean |
- | | | Percreta: through serosa| Hysterectomy; Cell Saver|
- +------------------+------------------------------+---------------------------+---------------------------+
- | **Uterine | • Sudden tearing abd. pain | • Complete disruption of | • Emergent exploratory |
- | Rupture** | • Loss of fetal station | all uterine wall layers | laparotomy; fetal extrac|
- | | • Cessation of contractions | • #1 risk: Prior classic | • Massive fluid resuscit. |
- | | • Sudden maternal shock | (vertical) C/S scar | • Uterine repair vs hyst. |
+------------------+------------------------------+---------------------------+---------------------------+ [PLACENTA ACCRETA SPECTRUM (PAS) DEPTH]
- Normal Decidua **ACCRETA (~75%)** **INCRETA (~15%)** **PERCRETA (~10%)**
- ================ ==================== ==================== ====================
- [ Placenta ] [ Placenta ] [ Placenta ] [ Placenta ]
- --------------- -------------------- -------------------- --------------------
- [Decidua Basalis] (No Decidua Layer) (No Decidua Layer) (No Decidua Layer)
- --------------- -------------------- -------------------- --------------------
- [ Myometrium ] [Attaches to Myomet] [Invades into Myomet] [Penetrates THROUGH]
- --------------- -------------------- -------------------- --------------------
- [Uterine Serosa] [ Uterine Serosa ] [ Uterine Serosa ] >>> Invades Bladder/
- >>> Pelvic Viscera
- 4. Amniotic Fluid Embolism (AFE) & The A-OK Protocol
Amniotic Fluid Embolism (also termed Anaphylactoid Syndrome of Pregnancy ) occurs in 1 : 40 , 000 1:40,000 1 : 40 , 000 deliveries and is characterized by entry of amniotic fluid, fetal cells, and procoagulants into the maternal venous circulation.
Biphasic Pathophysiology
Phase 1 (Acute Pulmonary Vasospasm & Right Heart Failure - First 30 Minutes):
Amniotic fluid elements trigger massive release of endogenous vasoactive mediators (thromboxane A2, endothelin, serotonin).
Intense pulmonary vasoconstriction causes acute pulmonary hypertension, acute right ventricular failure (cor pulmonale), severe ventilation-perfusion mismatch with right-to-left shunting, profound hypoxemia, and sudden cardiovascular collapse / cardiac arrest.
Phase 2 (Left Heart Failure & Consumptive Coagulopathy):
Surviving patients transition into left ventricular failure, cardiogenic shock, and non-cardiogenic pulmonary edema (capillary leak).
Procoagulants in amniotic fluid trigger widespread consumptive coagulopathy / Disseminated Intravascular Coagulation (DIC) with explosive hyperfibrinolysis within minutes, manifesting as massive hemorrhage from all mucosal surfaces and puncture sites. [BIPHASIC PATHOPHYSIOLOGY OF AFE]
- [Entry of Amniotic Fluid / Fetal Antigens into Maternal Blood]
- |
- v
- ===========================================
- >>> PHASE 1: ACUTE RV PULMONARY PHASE <<<
- ===========================================
- Intense Pulmonary Vasoconstriction
- Acute Cor Pulmonale (RV Failure & Dilation)
- Profound Hypoxemia ($V/Q$ Shunting) & Shock / Arrest
- |
- v
- ===========================================
- >>> PHASE 2: LV FAILURE & CONSUMPTIVE DIC <<<
- ===========================================
- Left Ventricular Dysfunction & Flash Pulmonary Edema
- Massive Consumption of Fibrinogen & Platelets
- Fulminant DIC with Torrential Bleeding
- Resuscitation & The Evidence-Based "A-OK" Protocol
Immediate ACLS & Airway: Intubate with 100 % O 2 100\% \text{ O}_2 100% O 2 , institute high-quality chest compressions with continuous 15 ∘ 15^\circ 1 5 ∘ left uterine displacement.
Perimortem Cesarean Delivery (Resuscitative Hysterotomy): If maternal cardiac arrest occurs and spontaneous circulation (ROSC) is not achieved within 4 minutes , initiate emergent Cesarean delivery immediately at the bedside, aiming for complete fetal delivery within 5 minutes . Evacuation of the gravid uterus eliminates aortocaval compression, improves venous return, and restores thoracic compliance, dramatically improving maternal resuscitation success.
The "A-OK" Pharmacologic Protocol:
Atropine ( 0.8 − 1.0 mg 0.8 - 1.0 \text{ mg} 0.8 − 1.0 mg IV): Blocks vagally mediated cardiopulmonary reflexes, severe bradycardia, and vagal pulmonary vasospasm.
Ondansetron ( 8 mg 8 \text{ mg} 8 mg IV): A selective 5 − H T 3 5-HT_3 5 − H T 3 receptor antagonist; blocks serotonin release from activated, degranulating platelets, thereby blunting serotonin-induced pulmonary vasoconstriction and right heart failure.
Ketorolac ( 30 mg 30 \text{ mg} 30 mg IV): Cyclooxygenase (COX) inhibitor; blocks the production of thromboxane A2 and vasoconstrictive prostaglandins from the arachidonic acid cascade.
Coagulopathy Management: Activate Massive Transfusion Protocol (MTP 1 : 1 : 1 1:1:1 1 : 1 : 1 ). Administer Cryoprecipitate ( 10 − 20 units 10 - 20 \text{ units} 10 − 20 units ) or Fibrinogen Concentrate to maintain fibrinogen > 200 mg/dL >200 \text{ mg/dL} > 200 mg/dL . Administer Tranexamic Acid ( 1 g 1 \text{ g} 1 g IV) to inhibit hyperfibrinolysis.